Skip to main content

AstraZeneca gets EU backing for targeted breast cancer therapies

Breast cancer patients may now benefit from two of AstraZeneca's existing therapies. The EU has recommended lynparza and enhertu to treat high-risk breast cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.